Canada has the potential to revolutionize its approach to rare genetic diseases, but it requires a paradigm shift in how it views and invests in data infrastructure. The country has already made significant strides in developing innovative programs and infrastructure, but these efforts are often isolated and underfunded. It's time for Canada to embrace a more integrated and equitable system, one that treats data sharing as a core component of healthcare and research.
The importance of data sharing cannot be overstated. Accurate diagnosis of rare diseases relies on comparing genomic and clinical data from thousands of individuals. This requires access to large-scale datasets, and Canada has the opportunity to lead the way in this area. The All for One Data Sharing Agreement and the Canadian Open Genetics Repository are examples of initiatives that promote responsible data sharing, but more needs to be done.
Canada must recognize data sharing as a fundamental diagnostic infrastructure, not an afterthought. When genomic testing is funded, the costs of responsible data sharing, interoperability, and legal/data governance support should be built into the model. This will ensure that the value of a test extends beyond the initial result, contributing to better interpretation for future patients.
Establishing national standards for rare disease testing and data is another crucial step. Canada needs to adopt and enforce global standards for publicly funded genomic testing, including eligibility criteria, laboratory accreditation, and professional certification. Standardized collection of phenotype, genotype, variant interpretation, consent, and outcomes data will ensure seamless data sharing across labs, hospitals, registries, and research platforms, both within Canada and internationally.
But data sharing is not just about technology and standards. It's about trust and partnership. Patients, families, and communities must be partners in governance. Many rare disease communities have long advocated for their data to be used to accelerate diagnosis, research, and care. Trust is built not by avoiding data sharing, but by ensuring that sharing is purposeful, transparent, secure, reciprocal, and aligned with patient and community priorities.
Canada has the opportunity to create a more integrated and effective system for managing rare diseases. But it requires a national vision, sustained investment, and coordinated infrastructure. By embracing data sharing as a core component of healthcare and research, Canada can transform a collection of local successes into a more equitable and efficient system for persons living with rare genetic diseases. It's time for Canada to take the lead and make data sharing a priority, ensuring that every test, every unsolved case, every diagnosis, and every patient experience contributes to a stronger system for the next person.
